Sign In
Buy ZEAL
$17.59
+0 (+0%)
At Close: Jan 27, 2023
Zealand Pharma major shareholder announcement: Bank of America Corporation
12:05pm, Friday, 16'th Aug 2024
Company announcement – No. 40 / 2024 Zealand Pharma major shareholder announcement: Bank of America Corporation Copenhagen, Denmark, 16 August 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq:
Zealand Pharma Announces Financial Results for the First Half of 2024
01:00am, Thursday, 15'th Aug 2024
Company announcement - No. 39 / 2024 Zealand Pharma Announces Financial Results for the First Half of 2024 Very strong progress across R&D pipeline followed by substantial capital raise enabling furth
Missed Out on Eli Lilly? This Much Smaller Biotech Has 2 Promising Weight Loss Assets in its Portfolio
06:22am, Friday, 05'th Jul 2024
Zealand Pharma is a much smaller healthcare stock than Eli Lilly. It has multiple drug candidates with the potential to take market share in the lucrative anti-obesity market.
Zealand Pharma major shareholder announcement: Van Herk Investments
11:10am, Friday, 28'th Jun 2024
Company announcement – No. 38 / 2024 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark, 28 June 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CV
Zealand Pharma completes registration of capital increase
02:36am, Friday, 28'th Jun 2024
Company announcement – No. 36 / 2024 Zealand Pharma completes registration of capital increase NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALI
Company announcement – No. 35 / 2024 Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion NOT
Company announcement – No. 34 / 2024 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion
11:02am, Tuesday, 25'th Jun 2024
Company announcement – No. 33 / 2024 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion NOT FOR RELEASE, PUBLICATION OR
Zealand Pharma Shares Jump 17% After Positive Trial Results For Ozempic Competitor
10:46am, Friday, 21'st Jun 2024
Shares for Zealand Pharma rose by over 17% on Friday, after the Danish biotech firm announced positive trial results for petrelintide, a new weight loss drug the company said could compete against Nov
Zealand Pharma stock rallies 20%: what happened?
09:55am, Friday, 21'st Jun 2024
Zealand Pharma (CPH: ZEAL) rallied more than 20% this morning after reporting positive results from an early stage trial of its new weight loss treatment. The biotech firm is now trading at an all-t
Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide Bo
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
11:00am, Thursday, 13'th Jun 2024
Company announcement – No. 31 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 13, 2024 – Zealand Pharma A/S (“Zealan
Company announcement - No. 30 / 2024 Zealand Pharma announces that Boehringer Ingelheim's survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of pati
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL
06:29am, Thursday, 06'th Jun 2024
Company announcement - No. 29 / 2024 Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL Copenhagen, Denmark, June 6, 2
Press release – No. 6 / 2024 Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency Copenhagen, Denmark, M
